The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
Abstract
PURPOSE: A complete remission (CR) after first-line therapy is associated with longer progression-free survival (PFS). However, defining CR is not always easy because of the presence of residual masses. Metabolic imaging with fluorine-18 fluorodeoxyglucose ([18 F]FDG) positron emission tomography (PET) offers the ability to differentiate between viable and fibrotic inactive tissue. In this study, we evaluated the value of PET in detecting residual disease and, hence, predicting relapse after first-line treatment in patients with non-Hodgkin’s lymphoma (NHL). PATIENTS AND METHODS: Ninety-three patients with histologically proven NHL, who underwent a whole-body [18 F]FDG-PET study after completion of first-line chemotherapy and who had follow-up of at least 1 year, were included. Persistence or absence of residual disease on PET was related to PFS using Kaplan-Meier survival analysis. RESULTS: Sixty-seven patients showed a normal PET scan after first-line chemotherapy; 56 of 67 remained in CR, with a median follow-up of 653 days. Nine of these patients with a residual mass considered as unconfirmed CR received additional radiotherapy. Only 11 of 67 patients relapsed (median PFS, 404 days). Persistent abnormal [18 F]FDG uptake was seen in 26 patients, and all of them relapsed (median PFS, 73 days). Because standard restaging also suggested residual disease, 12 patients received immediate secondary treatment. In 14 of 26 patients, only PET predicted persistent disease. From these patients, relapse was proven either by biopsy (n = 8) or by progressive disease on computed tomography or magnetic resonance imaging (n = 6). CONCLUSION: Persistent abnormal [18 F]FDG uptake after first-line chemotherapy in NHL is highly predictive for residual or recurrent disease. In relapsing patients, PFS was significantly shorter after a positive scan than after a negative scan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Self-citationMaximum Likelihood Reconstruction for Emission Tomography
Shepp, L. A., & Vardi, Y. (1982) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.1982.4307558 · Cited by 4,429
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 565
Harris, N. L. (1995) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(00)80051-4 · Cited by 527
Gianni, A. M., Bregni, M., Siena, S., Brambilla, C., Di Nicola, M., Lombardi, F., Gandola, L., Tarella, C., Pileri, A., Ravagnani, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705013361804 · Cited by 470
Römer, W., Hanauske, A.-R., Ziegler, S. I., Thödtmann, R., Weber, W., Fuchs, C., Enne, W., Herz, M., Nerl, C., Garbrecht, M., et al. (1998) · PubMed · doi:10.1182/blood.v91.12.4464 · Cited by 335
Cited by
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Self-citationArmitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Clinical Applications of PET in Oncology
Rohren, E. M., Turkington, T. G., & Coleman, R. E. (2004) · Radiology · doi:10.1148/radiol.2312021185 · Cited by 859
Positron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.-D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0272 · Cited by 494
Weber, W. A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C., & Schwaiger, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.004 · Cited by 493
New approaches for imaging tumour responses to treatment
Brindle, K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2289 · Cited by 460
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Patte, C., Auperin, A., Gerrard, M., Michon, J., Pinkerton, R., Sposto, R., Weston, C., Raphael, M., Perkins, S. L., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036673 · Cited by 430
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf256 · Cited by 410
Self-citationClinical Role of FDG PET in Evaluation of Cancer Patients
Kostakoglu, L., Agress, H., & Goldsmith, S. J. (2003) · RadioGraphics · doi:10.1148/rg.232025705 · Cited by 402
Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y., Wooldridge, J. E., Mottaghy, F. M., Rohren, E. M., Blumstein, N. M., Stolpen, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.891 · Cited by 387
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Stiff, P. J., Unger, J. M., Cook, J. R., Constine, L. S., Couban, S., Stewart, D. A., Shea, T. C., Porcu, P., Winter, J. N., Kahl, B. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301077 · Cited by 343
Moskowitz, C. H., Schöder, H., Teruya-Feldstein, J., Sima, C., Iasonos, A., Portlock, C. S., Straus, D., Noy, A., Palomba, M. L., O'Connor, O. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5942 · Cited by 326
The role of FDG-PET scans in patients with lymphoma
Seam, P., Juweid, M. E., & Cheson, B. D. (2007) · Blood · doi:10.1182/blood-2007-06-097238 · Cited by 304
Avril, N., Sassen, S., Schmalfeldt, B., Naehrig, J., Rutke, S., Weber, W. A., Werner, M., Graeff, H., Schwaiger, M., & Kuhn, W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.965 · Cited by 283
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Barrington, S. F., & Kluge, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3690-8 · Cited by 281
Role of Functional Imaging in the Management of Lymphoma
Cheson, B. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5225 · Cited by 280
FDG PET/CT-based response assessment in malignancies
Parihar, A. S., Dehdashti, F., & Wahl, R. L. (2023) · RadioGraphics · doi:10.1148/rg.220122 · Cited by 53
“The changes in glucose metabolism often precede any structural changes in tumor size, enabling an earlier assessment of response (25).”
Metadata
- Authors
- Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-01-15
- Volume
- 19
- Issue
- 2
- Pages
- 414-419
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2098871445
- Cited by
- 465
- References
- 22
- FWCI
- 19.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.